BioAffinity Technologies Inc. stocks have been trading up by 33.27 percent amid heightened optimism surrounding its latest diagnostic advancements.
Click Here for a Millionaire's POV on Trading BIAF
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Nationwide federal distribution deal with AvMEDICAL gives CyPath Lung direct access to VA and other U.S. government healthcare systems through established procurement channels and a focused sales force.
- Management is pushing CyPath Lung beyond early detection into post-treatment surveillance, targeting lung cancer survivors at high risk of recurrence and new primary tumors.
- Upcoming H.C. Wainwright conference appearance should spotlight BIAF’s commercial traction and platform expansion to a broader base of Wall Street-focused traders.
- Nasdaq compliance has been restored for BIAF common stock and warrants, removing an immediate delisting threat and stabilizing the trading backdrop for the name.
Live Update At 09:18:54 EDT: On Thursday, September 17, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 33.27%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
BIAF is trading like a classic low-float biotech with news-driven spikes and sharp pullbacks. In recent days, bioAffinity Technologies ran from $4.56 on 2026/08/31 to a high above $20 on 2026/09/04 before sliding back toward the mid-single digits. That’s pure volatility fuel for active traders.
On the fundamentals, BIAF is still very much an early-stage commercial story. The company generated about $1.51M in revenue last quarter and roughly $6.11M over the trailing period, but it is burning cash to build the CyPath Lung franchise. Gross margin around 52.6% shows the underlying test economics can be attractive, yet profit margins are deeply negative and returns on equity and assets are heavily in the red.
More Breaking News
- Nokia Stock Pops As AI, Telxius Deal And Index Return Shift The Narrative
- GNRC Soars As Amazon Data Center Deal Rewrites The Story
- FLNC Stock Slides As Guidance Cut Rattles Traders
- Tempus AI (TEM) Extends Rally After Earnings Beat And $1.5B Deal
The latest filing shows an operating cash outflow of roughly $3.2M for the quarter, partly offset by about $2.69M from stock issuance. Cash stood near $2.43M at period end, with modest debt and a current ratio of 1.4, signaling limited but real runway. For traders, that mix—high revenue growth off a small base, steep losses, and constant need for capital—creates a setup where every commercial or financing headline can move BIAF aggressively.
Why Traders Are Watching BIAF Right Now
bioAffinity Technologies has stacked several meaningful catalysts in a short window, and the tape reflects it. BIAF ripped from single digits to the $20 area on 2026/09/04 before retracing, a pattern you often see when a small-cap biotech suddenly looks “real” to the market.
The anchor news is the nationwide federal distribution agreement with AvMEDICAL. This deal puts CyPath Lung directly into the procurement channels of the Department of Veterans Affairs and other federal healthcare systems. For BIAF, that means tapping into a large, steady buyer base without building a massive in-house government sales operation. AvMEDICAL already has the sales force and IDIQ contracting infrastructure; BIAF just plugs its test into that machine. Traders love this kind of leverage story because it can change revenue expectations fast if adoption ramps.
At the same time, bioAffinity Technologies is pushing CyPath Lung beyond early detection into post-treatment surveillance. Lung cancer survivors face high recurrence risk and usually rely on periodic imaging. If CyPath Lung becomes a standard adjunct test in that survivorship setting, BIAF gains a second, repeat-use market for the same core product. More tests per patient and a broader use case can support a higher long-term revenue ceiling.
Another piece many traders overlook: BIAF regained full Nasdaq compliance for both its common shares and warrants. That removes a major overhang. Delisting risk keeps a lot of funds and day traders away. With that box checked, liquidity and borrow availability can stabilize, making it easier to trade BIAF around news.
Add in management’s upcoming corporate update and one-on-one meetings at the H.C. Wainwright Global Investment Conference, and you have a clear visibility event. Conferences like this often act as mini-catalysts—sometimes the news is just better storytelling and detailed guidance, but for thin names like BIAF, that can be enough to light up the tape again.
Conclusion
For active traders, BIAF is now a classic story of execution versus runway. On one side, bioAffinity Technologies has a noninvasive lung cancer diagnostic with solid margins, a fresh federal distribution deal via AvMEDICAL, and a strategy to extend CyPath Lung into survivor surveillance. On the other, the financials still show heavy operating losses, high negative returns, and ongoing reliance on equity raises to fund the build-out.
The recent price action—huge spike, sharp retrace, continued intraday swings between roughly $5 and $8 in premarket and early trading—tells you this is a momentum-driven name. BIAF will likely respond quickly to any new data, contract wins, or guidance out of the upcoming H.C. Wainwright appearance. The restored Nasdaq compliance removes a structural headwind and keeps BIAF and BIAFW in the game for larger pools of trading capital.
Traders following the Tim Sykes playbook will treat BIAF as a trade, not a marriage: watch the news feed, study the chart, and respect the risk. As Tim says, “I’m not here to be right, I’m here to trade well—cut losses fast and let the best setups come to you.” That aligns closely with the discipline many short-term traders emphasize around preparation and planning; as Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.” For now, BIAF is one of those setups that belongs on the watchlist, with tight risk controls and clear exit plans. This coverage is for educational and research purposes only and is not advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.